Olema Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 11, 2024
OLMA$7.27-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(Amounts in thousands, except for share amounts)
| Accumulated | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders' | ||||||||||
| Shares · Amount · Capital · (Loss) Gain · Deficit · Equity | ||||||||||
| Balances at December 31, 2021 | 39,797,263 | 3 | 388,904 | (149) | (104,190) | 284,568 | ||||
| Stock-based compensation expense | — | — | 18,453 | — | — | 18,453 | ||||
| Employee stock purchase plan expense | — | — | 376 | — | — | 376 | ||||
| Issuance of shares under employee stock purchase plan | 177,112 | — | 330 | — | — | 330 | ||||
| Exercise of stock options | 87,490 | — | 146 | — | — | 146 | ||||
| Vesting of early exercised stock options | 27,958 | — | 124 | — | — | 124 | ||||
| Vesting of restricted stock awards | 197,274 | — | — | — | — | — | ||||
| Net unrealized loss on marketable securities | — | — | — | (1,664) | — | (1,664) | ||||
| Net loss | — | — | — | — | (104,787) | (104,787) | ||||
| Balances at December 31, 2022 | 40,287,097 | $ | 3 | $ | 408,333 | $ | (1,813) | (208,977) | $ | 197,546 |
| Issuance of shares under equity private placement, net of issuance costs of $264 | 13,211,381 | 1 | 129,735 | — | — | 129,736 | ||||
| Stock-based compensation expense | — | — | 16,804 | — | — | 16,804 | ||||
| Exercise of stock options | 733,867 | — | 2,722 | — | — | 2,722 | ||||
| Issuance of shares under employee stock purchase plan | 333,503 | — | 1,050 | — | — | 1,050 | ||||
| Employee stock purchase plan expense | — | — | 452 | — | — | 452 | ||||
| Vesting of early exercised stock options | 18,640 | — | 80 | — | — | 80 | ||||
| Vesting of restricted stock awards | 191,296 | — | — | — | — | — | ||||
| Vesting of performance-based restricted stock unit awards | 217,000 | — | — | — | — | — | ||||
| Net unrealized gain on marketable securities | — | — | — | 2,160 | — | 2,160 | ||||
| Net loss | — | — | — | — | (96,655) | (96,655) | ||||
| Balances at December 31, 2023 | 54,992,784 | $ | 4 | $ | 559,176 | $ | 347 | (305,632) | $ | 253,895 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.